Company: Incyte
Tags: pipeline, compensation, rumors
Incyte leadership keeps saying Jakafi is protected and the data package is defensible against biosimilars. What they don't say is that payer contracts are already shifting in anticipation. I had two accounts get converted to biosimilar-preferred before any biosimilar even launched in my indication. Payers are moving preemptively. If your Incyte comp is heavily weighted toward Jakafi volume you should be having a serious conversation with your DM about what 2027 looks like. I'm not saying jump ship but I'm saying don't wait until it's obvious. The signs are there now.
17 upvotes · 0 comments